Fig. 5: The combination therapy of BEZ235 and ABT263 potently represses tumor growth in vivo | Cell Death & Disease

Fig. 5: The combination therapy of BEZ235 and ABT263 potently represses tumor growth in vivo

From: Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer

Fig. 5

a Tumor-bearing nude mice were treated with vehicle, BEZ235 (15 mg/kg) and/or ABT263 (25 mg/kg) for 4 weeks, and tumor volumes were measured every 2 days over 3 weeks. Error bar, mean ± SEM (n ≥ 4 per group). *P < 0.05 and ***P < 0.001 vs. vehicle group. b Analysis of tumor volume changes in mice after different treatments as in (A). Error bar, mean ± SEM (n ≥ 4 per group). *P < 0.05 and ***P < 0.001 vs. vehicle group. c Representative images of tumors collected from tumor-bearing nude mice following treatments as indicated for 4 weeks (left). Quantification analysis of tumor weights is shown in histogram (right). Error bar, mean ± SEM (n ≥ 4 per group). *P < 0.05 and ***P < 0.001 vs. vehicle group. d Immunohistochemical (IHC) analysis for changes of cleaved-caspase 3 expression in harvested tumors following different treatments as indicated. Representative images are shown (magnification: ×40). e Immunoblotting analysis of expressional changes of cleaved-caspase 3 in collected tumors from different groups. Each lane in indicated group represents a tumor sample collected from an individual mouse.

Back to article page